title: Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients.
abstract: The pharmacokinetics of thalidomide in nine human immunodeficiency virus-infected patients were studied. Single doses of thalidomide were well absorbed, with mean peak concentrations (+/- standard deviations) of 1.17 +/- 0.21 and 3.47 +/- 1.14 microg/ml in the 100- and 300-mg dosing groups, respectively, and the mean elimination half-life was approximately 6 h. Adverse effects were mild, with drowsiness being reported for seven of nine patients.
authors.affiliation: Department of Pharmacy, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA. spisc@nih.gov
authors.forename: S C
authors.initials: SC
authors.lastname: Piscitelli
authors.forename: W D
authors.initials: WD
authors.lastname: Figg
authors.forename: B
authors.initials: B
authors.lastname: Hahn
authors.forename: G
authors.initials: G
authors.lastname: Kelly
authors.forename: S
authors.initials: S
authors.lastname: Thomas
authors.forename: R E
authors.initials: RE
authors.lastname: Walker
mesh_terms: D000328:Adult; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D015658:HIV Infections / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013792:Thalidomide / Q000493:pharmacokinetics*
chemical_list: D013792:Thalidomide